News about "Lirafugratinib efficacy"

US FDA Approves Lirafugratinib for Cholangiocarcinoma

US FDA Approves Lirafugratinib for Cholangiocarcinoma

US FDA has approved lirafugratinib for previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma.

Lirafugratinib Efficacy | 25/09/2026 | By News Bureau


 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members